MEDIPOST disclosed on 28 April that administration in first patient for 1 and 2a clinical trial of ‘NEUROSTEM^®’ a Alzheimer’s dementia treatment drug using stem cell was successfully carried out.

This patient administration was carried out at Samsung Seoul Hospital on 15 April under supervision of Lecturer Deok Ryeol Na of the Department of Neurology, and no adverse events or particularities were observed during the 2 weeks of initial observation period.

MEDIPOST and Samsung Seoul Hospital will verify the efficacy of ‘NEUROSTEM^®’ as they carry out clinical trial on 40 dementia patients for around 2 years. This clinical trial is the world’s first challenge to overcome dementia using stem cell, therefore is gathering the attention of the medical and academic arena all over the world including large pharmaceutical companies of USA and Europe.

Related to this, MEDIPOST personnel stated that “we have the know-how of having succeeded in development of ‘the world’s first same type stem cell treatment drug’ in 2012 and the pre-phase and phase 1 clinical trials of ‘NEUROSTEM^®’ have already been successfully completed, therefore good results are anticipated for this clinical trial also”.

‘NEUROSTEM^®’ is made from mesenchyme stem cell extracted from cord blood (blood from umbilical cord), and MEDIPOST is anticipating that prevention will also be possible as well as fundamental treatment.

According to animal testing, ‘NEUROSTEM^®’ decreases the amyloid beta-protein which causes toxicity in neurons and inhibit the destruction of brain nerve cells.